CMV infections after hematopoietic stem cell transplantation

This publication has 29 references indexed in Scilit:

• Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
  Blood, 2007
• Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation
  Blood, 2006
• The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
  Blood, 2004
• Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
  Transplantation and Cellular Therapy, 2004
• Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products
  Blood, 2003
• Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
  Blood, 2002
• High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)–Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV Infection
  The Journal of Infectious Diseases, 2002
• Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes
  Blood, 2001
• Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
  Blood, 2001
• Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
  The Lancet, 1994